Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE To Adjust Drug Appraisal Standards So Terminally Ill Patients Can Access More Therapies

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed cost-effectiveness criteria allow medicines in U.K. to be judged on ability to substantially extend life.

You may also be interested in...

Drug Price Versus Value: British Pharma Plans Public Debate In November

Having called for a public debate on how the United Kingdom values and provides access to new medicines, the Association of the British Pharmaceutical Industry is organizing to make it happen

U.K. Drug Spending Plan Balances 5% Cut With Increased Access

The U.K. National Health Service could save approximately £310 million in branded drug costs in 2009 under a preliminary agreement between the government and the pharmaceutical industry

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts